Genetic alterations affecting the GNAS complex locus are responsible for several inherited disorders. Consistent with the parent-of-origin-specific expression of Gsα in some tissues, the phenotypes that are derived from these mutations depend on the parent transmitting the mutation. Pseudohypoparathyroidism (PHP) type I refers to partial or complete end-organ resistance to the actions of parathyroid hormone (PTH) and is characterized by a failure to increase urinary cAMP and urinary phosphate excretion in response to exogenous PTH administration [2] [3] [4] 24] . In PHP-II, nephrogenous cAMP generation in response to exogenous PTH administration is normal, but the urinary excretion of phosphate is impaired [25] . Although the common biochemical features of PHP are hypocalcemia, hyperphosphatemia, and elevated PTH levels, Albright hereditary osteodystrophy (AHO) is a Multiple imprinted sense and antisense transcripts from the complex GNAS locus. Exons 1-13 encode Gsα, which is biallelic in most tissues. Several other transcripts arise from differentially methylated promoters, including the maternally expressed NESP55 and the paternally expressed XLαs and A/B (also referred to as 1A or 1') and the neural transcript of Gsα and XLαs as GsαN1 and XLαsN1, respectively. All of these transcripts use individual first exons that splice onto exons 2-13 of GNAS . Another noncoding transcript is also derived from the paternal GNAS allele by using its own exons, but this transcript is made from the antisense strand ( AS transcript, also referred to as Nespas in mice). Boxes and connecting lines depict exons and introns, respectively. Maternal (Mat) and paternal (Pat) GNAS products are illustrated above and below the gene structure, respectively, with splicing patterns indicated by broken lines. + indicate methylated DMR promoters either on the paternal allele ( NESP55 ) or on the maternal allele ( XLαs , A/B, AS exon 1). Please note that the figure is not drawn to scale.
part of the clinical picture in PHP-Ia, PHP-Ic, and occasionally PHP-Ib ( table 1 ) . The features of AHO, as described originally by Albright et al. [26] , include obesity with a round face, short stature, brachydactyly, subcutaneous ossifications, and mental retardation (see below for details).
PHP-Ia and PHP-Ic
PHP-Ia is caused by heterozygous mutations located throughout the Gsα -coding GNAS exons. Homozygous mutations that completely disrupt Gsα activity seem to be incompatible with life, as judged by embryonic lethality observed in mice with homozygous ablation of Gnas and by the absence of any homozygous mutations described in humans; however, a single case having a compound heterozygous mutation with 10-20% Gsα activity has been reported [2, 4, 27] .
Typically, the heterozygous mutations described in patients with PHP-Ia lead to impaired cAMP generation due to unstable or no Gsα protein from the mutant allele, or impaired stimulation of adenylyl cyclase by the mutant protein. This is evidenced in biochemical assays in which patient-derived erythrocytes are used to complement membranes from turkey erythrocytes or S49 murine lymphoma cell membranes that lack endogenous Gsα activity [28, 29] . While these assays are utilized in the diagnosis of this disorder, a normal response in the presence of clinical features typical of PHP-Ia is the basis for the definition of PHP-Ic. Patients with PHP-Ic could carry mutations in other genes. However, Gsα mutants that are able to stimulate adenylyl cyclase but are defective in receptor coupling also appear fully functional when the erythrocyte Gsα bioactivity assay is performed by using direct stimulators of Gsα activity, such as a GTP analog, rather than a receptor agonist. Several cases with PHP-Ic have been shown to carry these receptor-uncoupling Gsα mutations, which are located near the C-terminal end of the Gsα molecule, consistent with the importance of this region in receptor interactions [2, 30, 31] . Nevertheless, the clinical phenotype of patients diagnosed with PHP-Ic is indistinguishable from that of patients diagnosed with PHP-Ia. By and large, genotype-phenotype correlation does not exist in diseases caused by inactivating GNAS mutations. However, a missense mutation (A366S) identified in 2 boys generates a temperature-sensitive Gsα mutant that causes testotoxicosis due to constitutive activity at the lower temperature of the testes [32] , but instability at body temperature, and an AVDT amino acid repeat insertion identified in 2 siblings, results in an unstable but overactive Gsα mutant that leads to transient neonatal diarrhea due to enhanced cAMP signaling in the gut [33] .
Consistent with the fact that Gsα signaling and cAMP production play important roles in the action of a variety of hormones, PTH resistance is not the sole hormonal defect that results from inactivating Gsα mutations. Additional hormonal abnormalities including hypothyroidism, growth hormone deficiency, and hypogonadism are also demonstrable in patients with PHP-Ia, reflecting target-organ resistance to TSH, growth hor- mone-releasing hormone (GHRH), and gonadotropins [2] [3] [4] .
Patients with PHP-Ia frequently present to the clinic with hypothyroidism due to end-organ resistance to TSH, which can sometimes be detected in neonatal screening for congenital hypothyroidism [2-4, 19-21, 34-36] . Although nearly all patients develop hypocalcemia, this defect often manifests itself later in life, usually after early childhood [35, 36] . It is therefore possible that PTH resistance is delayed. Since the development of hormone resistance depends critically on the silencing of Gsα expression from the normal paternal allele, if there is latency in PTH resistance, this finding would suggest that the allelic Gsα silencing in the proximal renal tubule is established after the early postnatal period. Accordingly, no evidence for predominant maternal expression of Gsα has been found in human fetal renal cortex [37] . Using mice heterozygous for ablation of either maternal or paternal Gnas exon 1, we found that the biochemical features of PTH resistance develop after early postnatal development, and that expression of Gsα is biallelic in the mouse renal proximal tubule during early postnatal life but becomes maternal with age [unpubl. data]. It is currently unknown whether the predominantly maternal expression of Gsα is established earlier in life in other tissues. Future studies are required to address this question.
PHP-Ia and Pseudopseudohypoparathyroidism
Maternally inherited mutations in GNAS exons 1-13 lead to PHP-Ia with multiple hormone resistance and AHO, whereas paternal inheritance of the same mutations leads to AHO features in the absence of hormone resistance. The latter condition is termed PPHP [38] . PHP-Ia and PPHP can be found in the same kindred, but not in the same sibship [39, 40] . This parent-of-originspecific mode of inheritance for hormone resistance could be explained by the tissue-specific paternal silencing of Gsα. In the case of a maternal mutation, a significant loss of Gsα activity exists in those tissues in which paternal Gsα is silenced, thus leading to hormone resistance. When inherited paternally, the same mutations do not severely reduce the Gsα activity and allow normal hormone responsiveness. On the other hand, heterozygous inactivating mutations of Gsα lead to 50% loss of protein activity in tissues in which Gsα expression is biallelic, such as skin fibroblasts, erythrocytes, white adipose tissue, bone, and growth plate chondrocytes [17, 28, 29, 34, 41, 42] . Clinical findings related to those tissues are due presumably to Gsα haploinsufficiency and are found independently of the parental origin of the mutation. The actions of some hormones, such as antidiuretic hormone and ACTH, seem to be unimpaired despite the 50% reduction in Gsα activity in their target tissues [34, 43, 44] , indicating a lack of haploinsufficiency. AHO features, which are fairly nonspecific, can be present in a patient regardless of the parental origin of the Gsα mutation. Thus, it is thought that AHO results primarily from Gsα haploinsufficiency in those tissues where Gsα expression is biallelic. Consistent with this interpretation, growth plate chondrocytes that lack either the maternal or the paternal Gsα allele differentiate into hypertrophic chondrocytes earlier than wild-type chondrocytes in a chimeric mouse model [42] . Likewise, mice with ablation of Gnas exon 1 develop subcutaneous ossifications regardless of whether the disrupted allele is inherited from the mother or the father [45] . Nonetheless, recent data from human studies have revealed that obesity and cognitive impairment occur predominantly in patients with PHP-Ia rather than PPHP [46, 47] , indicating that the mechanisms leading to these AHO features involve Gsα imprinting.
Progressive Osseous Heteroplasia
Progressive osseous heteroplasia (POH) is a severe, rare manifestation of AHO characterized by severe heterotopic ossification that affects deep connective tissue and skeletal muscle [48] . Patients with POH often lack any features of AHO or hormone resistance. Based on published cases, it appears that the great majority of GNAS mutations leading to POH are inherited paternally [49] [50] [51] , suggesting the involvement of a loss or impaired function of the paternally expressed protein in the development of the severe ossifications. GNAS mutations identified in patients with POH are the same as those found in PHP-Ia or PPHP, and it is unclear why some cases present only with PHP-Ia or PPHP while others develop POH [3, [48] [49] [50] [51] . This phenotypic variation and different disease presentation of a GNAS mutation might involve the genetic background, epigenetic changes, and/ or environmental factors.
Mouse Models of PHP-Ia
The homozygous disruption of Gnas exon 1, which is exclusively utilized by Gsα, causes embryonic lethality during early postimplantation stages, consistent with the essential roles of this protein in numerous cellular functions [52, 53] . Heterozygous disruption of this exon on the maternal allele ( Gnas E1m-/p+) leads to moderate (50%) preweaning mortality and edema at birth [52, 53] . Surviving mice show a phenotype similar to that observed in PHP-Ia patients, including obesity, a decreased metabolic rate, and PTH resistance [52, 54] ( table 2 ) . Evidence for TSH resistance was not observed in one of the mouse models in which Gnas exon 1 was ablated [53] , while elevated TSH was documented in another model [52] . This discrepancy likely reflects strain-specific differences, although it is conceivable that it results from the difference in the extent of the genomic deletion between these two models. Interestingly, mildly elevated PTH and TSH levels have been reported for one of the two knockout mod- [55] . The phenotype of Gnas E2m+/p-mice is strikingly similar to the phenotype of mice in which XLαs is ablated ( Gnasxl m+/p-mice) ( table 2 ), implicating the deficiency of this paternally expressed Gnas product in the phenotype [56, 57] .
The oedematous-small (Oed-Sml) is another mouse model of the Gnas locus in which a point mutation in Gnas exon 6 (V159E) is induced by ethylnitrosourea (ENU) [58, 59] ( table 2 ) . Maternally transmitted mutations result in microcardia with gross edema (Oed) ; note that neonatal edema has been reported for mice with maternal heterozygous Gnas exon 1 ablation [52, 53] . However, when this point mutation is transmitted paternally, the offspring shows growth retardation (Sml) , which is likely related to the disruption of the paternally expressed Gnas product XLαs [58] [59] [60] . Both of these maternal and paternal phenotypes are early postnatal and are associated with high lethality within this developmental period [59] . In surviving adult mice carrying this point mutation on the maternal allele, hypocalcemia, hyperphosphatemia, and elevated PTH levels have been documented, consistent with the findings observed in PHP-Ia patients [18] . Recent investigations have also revealed mildly elevated PTH and hypocalcemia in older (>12 months) Sml mice, but these biochemical changes have been accompanied by hypophosphatemia, unlike the findings in Oed mice and other mouse models with maternal Gsα ablation, which show hyperphosphatemia [61] .
Subcutaneous heterotopic ossifications, as seen in patients with AHO, have also been documented in mice heterozygous for Gnas exon 1 ablation and in Oed/Sml mice [45, 61] ( table 2 ) . By 1 year of age, nearly all male mice with these genetic modifications develop subcutaneous ossifications, but precursor lesions can be detected by histological analyses as early as 3 months of age [45] . Similar to the findings in patients with AHO, the ossifications develop regardless of the parent of origin, implicating the deficiency of biallically expressed Gsα in the pathogenesis. In mice heterozygous for Gnas exon 2 disruption, osseous lesions have not been detected, but instead calcified fibromas or angiofibromas of the skin are found by 4 months of age, independently of whether the maternal or the paternal Gnas exon 2 is disrupted [62] ( table 2 ).
PHP Type Ib: Hormone Resistance Caused by Epigenetic Alterations of GNAS
In certain patients, hormone resistance is confined to the renal proximal tubular action of PTH, and this form of PHP is defined as PHP type Ib [2] [3] [4] . Some PHP-Ib patients have been shown to have mildly elevated TSH levels, indicating TSH resistance [21] . Some recent studies have also shown that AHO features can exist in patients who have epigenetic abnormalities of GNAS that are typically found in PHP-Ib [63] [64] [65] [66] .
Autosomal Dominant PHP-Ib
Most PHP-Ib cases are sporadic, but some cases are familial and inherited in an autosomal dominant fashion (AD-PHP-Ib). Similar to the hormone resistance in PHPIa, the hormone resistance in PHP-Ib is inherited only from female obligate carriers [67, 68] , yet no mutations in GNAS exons encoding Gsα have been described in patients with PHP-Ib. On the other hand, a genetic linkage analysis has mapped AD-PHP-Ib to a locus within the telomeric end of chromosome 20q which comprises the GNAS locus [67] . It has subsequently been revealed that PHP-Ib patients have methylation defects within GNAS [68, 69] and, accordingly, various paternal uniparental disomies involving chromosome 20 have been documented in some PHP-Ib patients who lack the maternal methylation pattern in this locus [70] [71] [72] [73] [74] . The most consistent epigenetic abnormality in both sporadic and familial PHP-Ib is a loss of methylation in the exon A/B DMR, which is often the only methylation defect in AD-PHP-Ib cases ( fig. 2 ) [68, 69] .
In patients with AD-PHP-Ib, genetic studies have revealed deletions in the neighboring STX16 locus, the gene encoding syntaxin 16 [75, 76] . Recently, a large deletion removing GNAS exon NESP55 was discovered in a single AD-PHP-Ib family [77] . Both the STX16 and the NESP55 deletions are inherited from female obligate carriers, con- [75] [76] [77] . Interestingly, STX16 is located ∼ 220 kb centromeric of exon A/B and encodes a member of the SNARE family proteins involved in intracellular trafficking [78, 79] . STX16 is not an imprinted gene, and therefore it is thought that the deletion disrupts a regulatory element of GNAS controlling the methylation of exon A/B. However, a mouse model carrying a deletion of Stx16 exon 4-6, which is equivalent to the 3-kb STX16 deletion frequently found in AD-PHP-Ib cases, does not have PTH resistance or GNAS methylation abnormalities regardless of the parental origin of the genetic defect [80] , suggesting that this putative cis-acting regulatory element of Gnas is located in a different position in mice.
Some AD-PHP-Ib cases show methylation defects in multiple GNAS DMR. In 3 unrelated AD-PHP-Ib families in whom affected individuals showed methylation defects in all GNAS DMR, deletions of all or part of the NESP55 DMR have been identified, including exon NESP55 and exons 3 and 4 of the GNAS-AS1 transcript [81, 82] . In 2 families, the deletions are nearly identical and remove the entire NESP55 DMR [81] . In the third family, the sequences comprising exon NESP55 are preserved, but GNAS-AS1 transcript exons 3 and 4 are deleted along with a significant portion of intron 2 [82] . The deletions affecting the NESP55 DMR also point to a cisacting element regulating the imprinting of the maternal GNAS allele. In fact, maternal deletion of the entire Nesp55 DMR in mice leads to loss of all maternal Gnas methylation imprints, leading in kidneys to increased 1A transcription and decreased Gsα mRNA levels, and to hypocalcemia, hyperphosphatemia, and hyperparathyroidism; note that no methylation abnormality has been detected in mice that inherited this deletion paternally [83, 84] ( table 2 ) . Furthermore, the maternal Nesp55 deletion in mice leads to hypoglycemia and 100% mortality during the early postnatal period [83, 84] . Recent investigations have revealed that the loss of XLαs imprinting, which is associated with a two-fold increase in the expression of this Gnas transcript, is responsible for the early postnatal hypoglycemia and lethality in mice with maternal deletion of Nesp55 DMR [84] . Normalization of the XLαs expression level in the latter mice by crossing them with mice in which the paternal XLαs allele is disrupted allows generation of double-mutant offspring that show markedly improved survival, thus providing a viable model of human AD-PHP-Ib [84] ( table 2 ) . It should be noted that the early postnatal lethality and hypoglycemia phenotypes in the latter mice are not typical features of patients with PHP-Ib, although neonatal hypoglycemia has been described in a single patient with paternal UPD of chromosome 20q who had PHP-Ib and broad GNAS imprinting defects including a loss of XLαs imprinting [70] . The phenotypic consequence of XLαs loss of imprinting may be specific to mice or it may be compensated or masked by other genetic or environmental factors in humans.
Sporadic PHP-Ib
Epigenetic changes that involve multiple GNAS DMR are mostly observed in sporadic PHP-Ib patients [85] . As indicated above, some of these patients carry paternal uniparental disomy involving a part or the whole of chromosome 20q, but the genetic cause of these methylation abnormalities in most sporadic cases remains to be identified [70] [71] [72] [73] [74] 86] . De novo single or multiple base pair changes in the region spanning NESP55 /AS exons 3 and 4 are plausible or, as suggested previously [85] , these methylation changes could occur stochastically. Additionally, it is possible that the epigenetic abnormalities in sporadic cases, which tend to be incomplete, result from genetic defects in a trans-acting factor necessary for the maintenance of methylation at GNAS and, perhaps, some other imprinted loci. In fact, methylation defects in GNAS have been identified in combination with methylation defects in other loci in the context of certain other disorders [87, 88] . In addition, a recent study of sporadic PHP-Ib cases revealed methylation changes in the DLK1/GTL2 or the PEG1 / MEST locus [89] . The clinical significance of the loss of methylation at DLK1 / GTL2 , detected in one sporadic PHP-Ib case, could not be examined. On the other hand, the loss of methylation at PEG1 / MEST , found in another sporadic PHP-Ib case, could perhaps explain the finding that this case had the highest BMI within the study population [89] , given that the loss of the paternally expressed PEG1 / MEST gene causes embryonic growth retardation, and a loss of maternal methylation marks at this locus may therefore result in the biallelic expression of PEG1 / MEST and fetal overgrowth [90] .
Potential Roles of Other GNAS Transcripts in Physiology and Disease
As shown in figure 1 , multiple transcripts originate from the GNAS locus, but unlike Gsα these GNAS products have remained largely obscure in terms of their specific cellular roles.
XLαs Transcript
XLαs shares a significant portion of its amino acid sequence with Gsα, whereas the other GNAS products that utilize exons 2-13 do not have this portion as part of the primary protein structure (see below for details and possible exceptions). Therefore, XLαs appears to be an important Gsα variant that may have roles that are similar to the roles of the latter. While Gsα is expressed ubiquitously, XLαs displays a more discrete expression pattern; it is expressed primarily in neuroendocrine tissues, such as the pituitary and orexigenic neurons in the hypothalamus of neonatal and adult rodents [5, 12, 14, 56, [91] [92] [93] . Its expression has been detected in a number of other tissues and cells in humans and rodents, including pancreas, white and brown adipose tissue, platelets, kidney, and various types of muscle cells [5, 12, 14, 56, 93] . Studies have shown that XLαs can function as a distinct α-subunit of the heterotrimeric Gs signaling protein [54, [94] [95] [96] . In fact, XLαs remains more stably on the plasma membrane than Gsα and, at least under certain conditions, is able to produce receptor-stimulated cAMP formation more potently and in a more prolonged manner than Gsα [97] . Recently, hypermethylation of the XLαs DMR, along with reduced XLαs protein expression in platelets, was reported in certain patients who had Gs hypofunction in their platelets and an AHO-like phenotype in the absence of coding Gsα mutations [98] , thus supporting a Gsα-like role for XLαs. The phenotype of Gnasxl m+/p-mice is vastly different 237 from, and in many ways the opposite of, the phenotype of mice in which Gsα (but not XLαs) is ablated; note that the latter mice are heterozygous for ablation of Gsα exon 1 [52, 53] . On the other hand, the study of Gnasxl m+/pmice has clearly revealed that XLαs is essential for early postnatal adaptation to feeding and survival, as well as glucose counterregulation [56, 57] . Consistent with these findings, which were shown in some but not all of the other mouse models in which the XLαs transcript was ablated, some pediatric patients with perinatal developmental defects and intractable feeding difficulties have been reported to have large paternal deletions of GNAS [99, 100] . Furthermore, recent studies of patients with POH or PPHP have indicated that paternal GNAS mutations are associated with a low birth weight [101, 102] . Based on evidence from different mouse models, however, it remains plausible that some of the early postnatal phenotypes, such as poor suckling, observed in Gnasxl m+/p-mice and in patients with large paternal GNAS deletions reflect the ablation of other gene products that use exon XL but not XLαs itself [56, 57, 59, 103] . Recent analyses in mice have also implicated XLas functions in bone and mineral metabolism. As explained above, older (>12 months old) Sml mice were shown to have mild hypocalcemia, hypophosphatemia, and elevated serum PTH [61] . Moreover, mild hypocalcemia and marked hyperphosphatemia was documented in 10-day old Gnasxl m+/p-pups [84] . In addition, bone mineral density was found to be diminished in a mouse model in which both XLαs and XLαs-N1 was ablated together with loss of Gsα imprinting [103] .
A/B Transcript
The A/B transcript is biallelically expressed in patients with PHP-Ib due to a loss of methylation in its promoter [68] [69] [70] . It is thought that, under normal conditions, a trans-acting protein expressed in certain tissues, such as renal proximal tubules, binds to the unmethylated region at the exon A/B DMR and thereby silences -either directly or by blocking the effect of an enhancer elementthe promoter of Gsα, which is about 2 kb downstream [15, 18, 104] . While this is a plausible hypothesis, another possibility is that the activity of the A/B promoter results in transcriptional interference on the downstream Gsα promoter in a tissue-specific manner. Studies with various genetically manipulated mice have shown that the exon A/B (referred to as 1A in mice) DMR on the paternal allele is required for the tissue-specific paternal silencing of Gsα [18, 104] . In addition, evidence supporting a negative effect of A/B transcription on the Gsα promoter has been obtained by generating mice in which the A/B transcript was prematurely truncated [103] . Furthermore, the A/B transcript can code for a truncated Gsα-like protein by using an initiation codon in exon 2 [7] . Evidence for the existence of this protein could be obtained by analyzing fetal kidney lysates [105] . In transfected cells, overexpression of this A/B protein inhibited PTH-mediated and, less potently, TSH-mediated cAMP production, raising the possibility that the hormone resistance phenotype in PHP-Ib patients is due, at least partly, to the biallelic (i.e. doubled) expression of the A/B protein [105] .
NESP55 Transcript
NESP55 is a chromogranin-like neurosecretory protein. Its expression is often lost in patients with PHP-Ib due to a gain of methylation at its promoter [69, 70] . No phenotype, however, can be attributed to the loss of NESP55 expression in those patients, whose clinical findings seem to be apparently identical to the clinical findings of those who have normal NESP55 methylation [69, 106] . Ablation of the Nesp55 protein in mice is not associated with an early postnatal or developmental phenotype, but in adult mice it results in a mild behavioral phenotype that involves abnormal reactivity to novel environments [107] . On the other hand, an oocyte-specific Nesp55 transcript has been identified in mice, and premature termination of Nesp55 transcription through introduction of a polyadenylation cassette into the Gnas locus leads to a loss of methylation at exon A/B and, in some cases, at other Gnas DMR [108] . Thus, at least one of the important roles of NESP55 appears to be in the regulation of imprinting at this complex locus, and it appears likely that the maternal deletions of the NESP55 DMR in PHPIb patients result in a loss of GNAS methylation because they disrupt NESP55 transcription.
GNAS-AS1 Transcript
The GNAS-AS1 transcript (referred to as Nespas in mice) is a noncoding paternally expressed transcript [9, 10] . Studies in mice have shown that it is required for silencing Nesp55 expression on the paternal allele [109, 110] . Accordingly, one of the deletions identified in an AD-PHP-Ib kindred results in the reduction of GNAS-AS1 expression in unaffected carriers, who inherit this deletion paternally [82] , and these individuals show a partial loss of NESP55 methylation, indicating derepression of NESP55 transcription [82] . Also present in these unaffected carriers is a partial gain of methylation at exon A/B DMR [82] , consistent with a role of NESP55 transcription in regulating methylation of downstream GNAS DMR, as 238 explained above [108] . However, since the deletion identified in these unaffected carriers is located on the paternal allele [82] , the latter finding suggests that NESP55 transcription may perhaps regulate GNAS DMR not only in the female germ line but also in the male germ line or somatic tissues.
In summary, the imprinted GNAS complex locus, which gives rise to the ubiquitously expressed signaling protein Gsα and other imprinted gene products, is critical for the actions of many hormones, and genetic defects in this gene lead to PHP and related diseases. Although these human disorders have been explored for decades, further genetic studies, together with generation and investigations of mouse models, are required to improve their understanding at the genetic, molecular, and clinical levels.
